Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

Jean Jacques Kiladjian, Paola Guglielmelli, Martin Griesshammer, Guray Saydam, T. Masszi, Simon Durrant, Francesco Passamonti, Mark Jones, Huiling Zhen, Jingjin Li, Brian Gadbaw, Julian Perez Ronco, Mahmudul Khan, Srdan Verstovsek

Research output: Article

3 Citations (Scopus)

Abstract

Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving polycythemia vera-related symptoms in the Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care (RESPONSE) studies. This ad hoc analysis focuses on ruxolitinib in relation to IFN in the RESPONSE studies, with attention on the following: (1) safety and efficacy of ruxolitinib and best available therapy in patients who received IFN before study randomization, (2) safety and efficacy of IFN during randomized treatment in best available therapy arm, and (3) use of ruxolitinib after crossover from best available therapy in IFN-treated patients. IFN exposure before randomization had little effect on the efficacy or safety of ruxolitinib. In the randomized treatment arms, ruxolitinib was superior to IFN in efficacy [hematocrit control (RESPONSE = 60% of ruxolitinib vs 23% of IFN patients; RESPONSE-2 = 62% of ruxolitinib vs 15% of IFN patients)] and was tolerated better in hydroxyurea-resistant or hydroxyurea-intolerant patients. After crossing over to receive ruxolitinib, patients who had initially received IFN and did not respond had improved hematologic and spleen responses (62% of patients at any time after crossover) and an overall reduction in phlebotomy procedures. Rates and incidences of the most common adverse events decreased after crossover to ruxolitinib, except for infections (primarily grade 1 or 2). These data suggest that ruxolitinib is efficacious and well tolerated in patients who were previously treated with IFN. The RESPONSE (NCT01243944) and RESPONSE-2 (NCT02038036) studies were registered at clinicaltrials.gov.

Original languageEnglish
Pages (from-to)617-627
Number of pages11
JournalAnnals of Hematology
Volume97
Issue number4
DOIs
Publication statusPublished - ápr. 1 2018

Fingerprint

Interferons
Safety
Hydroxyurea
Polycythemia Vera
Phlebotomy
Random Allocation
Hematocrit
INCB018424
Therapeutics
Tablets
Spleen
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Kiladjian, J. J., Guglielmelli, P., Griesshammer, M., Saydam, G., Masszi, T., Durrant, S., ... Verstovsek, S. (2018). Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Annals of Hematology, 97(4), 617-627. https://doi.org/10.1007/s00277-017-3225-1

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. / Kiladjian, Jean Jacques; Guglielmelli, Paola; Griesshammer, Martin; Saydam, Guray; Masszi, T.; Durrant, Simon; Passamonti, Francesco; Jones, Mark; Zhen, Huiling; Li, Jingjin; Gadbaw, Brian; Perez Ronco, Julian; Khan, Mahmudul; Verstovsek, Srdan.

In: Annals of Hematology, Vol. 97, No. 4, 01.04.2018, p. 617-627.

Research output: Article

Kiladjian, JJ, Guglielmelli, P, Griesshammer, M, Saydam, G, Masszi, T, Durrant, S, Passamonti, F, Jones, M, Zhen, H, Li, J, Gadbaw, B, Perez Ronco, J, Khan, M & Verstovsek, S 2018, 'Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies', Annals of Hematology, vol. 97, no. 4, pp. 617-627. https://doi.org/10.1007/s00277-017-3225-1
Kiladjian, Jean Jacques ; Guglielmelli, Paola ; Griesshammer, Martin ; Saydam, Guray ; Masszi, T. ; Durrant, Simon ; Passamonti, Francesco ; Jones, Mark ; Zhen, Huiling ; Li, Jingjin ; Gadbaw, Brian ; Perez Ronco, Julian ; Khan, Mahmudul ; Verstovsek, Srdan. / Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. In: Annals of Hematology. 2018 ; Vol. 97, No. 4. pp. 617-627.
@article{ed0bc14c6f9d4ed2b8f9a0779ed09097,
title = "Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies",
abstract = "Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving polycythemia vera-related symptoms in the Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care (RESPONSE) studies. This ad hoc analysis focuses on ruxolitinib in relation to IFN in the RESPONSE studies, with attention on the following: (1) safety and efficacy of ruxolitinib and best available therapy in patients who received IFN before study randomization, (2) safety and efficacy of IFN during randomized treatment in best available therapy arm, and (3) use of ruxolitinib after crossover from best available therapy in IFN-treated patients. IFN exposure before randomization had little effect on the efficacy or safety of ruxolitinib. In the randomized treatment arms, ruxolitinib was superior to IFN in efficacy [hematocrit control (RESPONSE = 60{\%} of ruxolitinib vs 23{\%} of IFN patients; RESPONSE-2 = 62{\%} of ruxolitinib vs 15{\%} of IFN patients)] and was tolerated better in hydroxyurea-resistant or hydroxyurea-intolerant patients. After crossing over to receive ruxolitinib, patients who had initially received IFN and did not respond had improved hematologic and spleen responses (62{\%} of patients at any time after crossover) and an overall reduction in phlebotomy procedures. Rates and incidences of the most common adverse events decreased after crossover to ruxolitinib, except for infections (primarily grade 1 or 2). These data suggest that ruxolitinib is efficacious and well tolerated in patients who were previously treated with IFN. The RESPONSE (NCT01243944) and RESPONSE-2 (NCT02038036) studies were registered at clinicaltrials.gov.",
keywords = "Chronic myeloproliferative neoplasms, Interferon, Polycythemia vera, Ruxolitinib",
author = "Kiladjian, {Jean Jacques} and Paola Guglielmelli and Martin Griesshammer and Guray Saydam and T. Masszi and Simon Durrant and Francesco Passamonti and Mark Jones and Huiling Zhen and Jingjin Li and Brian Gadbaw and {Perez Ronco}, Julian and Mahmudul Khan and Srdan Verstovsek",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s00277-017-3225-1",
language = "English",
volume = "97",
pages = "617--627",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

AU - Kiladjian, Jean Jacques

AU - Guglielmelli, Paola

AU - Griesshammer, Martin

AU - Saydam, Guray

AU - Masszi, T.

AU - Durrant, Simon

AU - Passamonti, Francesco

AU - Jones, Mark

AU - Zhen, Huiling

AU - Li, Jingjin

AU - Gadbaw, Brian

AU - Perez Ronco, Julian

AU - Khan, Mahmudul

AU - Verstovsek, Srdan

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving polycythemia vera-related symptoms in the Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care (RESPONSE) studies. This ad hoc analysis focuses on ruxolitinib in relation to IFN in the RESPONSE studies, with attention on the following: (1) safety and efficacy of ruxolitinib and best available therapy in patients who received IFN before study randomization, (2) safety and efficacy of IFN during randomized treatment in best available therapy arm, and (3) use of ruxolitinib after crossover from best available therapy in IFN-treated patients. IFN exposure before randomization had little effect on the efficacy or safety of ruxolitinib. In the randomized treatment arms, ruxolitinib was superior to IFN in efficacy [hematocrit control (RESPONSE = 60% of ruxolitinib vs 23% of IFN patients; RESPONSE-2 = 62% of ruxolitinib vs 15% of IFN patients)] and was tolerated better in hydroxyurea-resistant or hydroxyurea-intolerant patients. After crossing over to receive ruxolitinib, patients who had initially received IFN and did not respond had improved hematologic and spleen responses (62% of patients at any time after crossover) and an overall reduction in phlebotomy procedures. Rates and incidences of the most common adverse events decreased after crossover to ruxolitinib, except for infections (primarily grade 1 or 2). These data suggest that ruxolitinib is efficacious and well tolerated in patients who were previously treated with IFN. The RESPONSE (NCT01243944) and RESPONSE-2 (NCT02038036) studies were registered at clinicaltrials.gov.

AB - Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving polycythemia vera-related symptoms in the Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care (RESPONSE) studies. This ad hoc analysis focuses on ruxolitinib in relation to IFN in the RESPONSE studies, with attention on the following: (1) safety and efficacy of ruxolitinib and best available therapy in patients who received IFN before study randomization, (2) safety and efficacy of IFN during randomized treatment in best available therapy arm, and (3) use of ruxolitinib after crossover from best available therapy in IFN-treated patients. IFN exposure before randomization had little effect on the efficacy or safety of ruxolitinib. In the randomized treatment arms, ruxolitinib was superior to IFN in efficacy [hematocrit control (RESPONSE = 60% of ruxolitinib vs 23% of IFN patients; RESPONSE-2 = 62% of ruxolitinib vs 15% of IFN patients)] and was tolerated better in hydroxyurea-resistant or hydroxyurea-intolerant patients. After crossing over to receive ruxolitinib, patients who had initially received IFN and did not respond had improved hematologic and spleen responses (62% of patients at any time after crossover) and an overall reduction in phlebotomy procedures. Rates and incidences of the most common adverse events decreased after crossover to ruxolitinib, except for infections (primarily grade 1 or 2). These data suggest that ruxolitinib is efficacious and well tolerated in patients who were previously treated with IFN. The RESPONSE (NCT01243944) and RESPONSE-2 (NCT02038036) studies were registered at clinicaltrials.gov.

KW - Chronic myeloproliferative neoplasms

KW - Interferon

KW - Polycythemia vera

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=85042733285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042733285&partnerID=8YFLogxK

U2 - 10.1007/s00277-017-3225-1

DO - 10.1007/s00277-017-3225-1

M3 - Article

C2 - 29396713

AN - SCOPUS:85042733285

VL - 97

SP - 617

EP - 627

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 4

ER -